Chen Bo, Zhao Xing, Zhang Juying
Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Pharm Stat. 2022 Mar;21(2):317-326. doi: 10.1002/pst.2171. Epub 2021 Sep 28.
Two-stage single arm designs are widely used in phase II clinical trials with binary endpoints. The trial may be stopped early due to insufficient positive responses in the first stage. There may be some enrolled subjects who have yet to respond by the end of the first stage, and their data are ignored if the first stage results in rejection of the trial. It is possible that the result after the first stage is rejection by a slim margin, while the results of pipeline subjects are quite positive. In this case, combining the data from the two sources may provide a valuable opportunity to rescue a promising treatment that was mistakenly rejected. We propose a novel double-check design to take advantage of the pipeline subjects' data to establish a rescue criterion based on two-stage design. When the rescue criterion is met, the decision to reject the trial at the end of the first stage can be reversed, allowing the trial to continue. A derivation based on a binomial distribution shows that the double-check strategy can strictly preserve the type I error rate. Further examination shows that the strategy can provide a slight increase in overall power and a substantial increase in conditional power when the proportion of positive response at the end of the first stage is at the margin. The extra rescue opportunity's cost is pretty low, only a slight increasing in the expected sample size.
两阶段单臂设计广泛应用于具有二元终点的II期临床试验。由于第一阶段阳性反应不足,试验可能会提前终止。可能有一些入组的受试者在第一阶段结束时仍未产生反应,如果第一阶段导致试验被拒绝,他们的数据将被忽略。有可能第一阶段的结果以微弱优势被拒绝,而后续受试者的结果却相当积极。在这种情况下,合并来自这两个来源的数据可能会提供一个宝贵的机会来挽救一种被错误拒绝的有前景的治疗方法。我们提出了一种新颖的双重检查设计,利用后续受试者的数据,基于两阶段设计建立一个挽救标准。当满足挽救标准时,在第一阶段结束时拒绝试验的决定可以被推翻,使试验得以继续。基于二项分布的推导表明,双重检查策略可以严格保持I型错误率。进一步研究表明,当第一阶段结束时阳性反应的比例处于临界值时,该策略可以使总体检验效能略有提高,条件检验效能大幅提高。额外挽救机会的成本相当低,仅使预期样本量略有增加。